Evidence map›Paper›PMID 33923843›Full record

ReviewMolecules (Basel, Switzerland)2021

Valorization of Winemaking By-Products as a Novel Source of Antibacterial Properties: New Strategies to Fight Antibiotic Resistance.

Adriana Silva, Vanessa Silva, Gilberto Igrejas, Isabel Gaivão, Alfredo Aires, Naouel Klibi, Maria de Lurdes Enes Dapkevicius, Patrícia Valentão, Virgílio Falco, Patrícia Poeta

Abstract readReview
In one paragraph

Review in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed.

  1. Article
  2. Supercritical COMolecules (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Biowaste Valorization: The Wine Industry Case.Advances in biochemical engineering/biotechnology · 2025
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Adriana SilvaMicrobiology and Antibiotic Resistance Team (MicroART), Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro (UTAD), 5000-801 Vila Real, Portugal.
Vanessa SilvaMicrobiology and Antibiotic Resistance Team (MicroART), Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro (UTAD), 5000-801 Vila Real, Portugal.ORCID 0000-0001-9406-8433
Gilberto IgrejasDepartment of Genetics and Biotechnology, University of Trás-os-Montes and Alto Douro (UTAD), 5000-801 Vila Real, Portugal.ORCID 0000-0002-6365-0735
Isabel GaivãoDepartment of Genetics and Biotechnology, University of Trás-os-Montes and Alto Douro (UTAD), 5000-801 Vila Real, Portugal.ORCID 0000-0003-4461-7021
Alfredo AiresCentre for the Research and Technology of Agro-Environmental and Biological Sciences (CITAB), University of Trás-os-Montes and Alto Douro (UTAD), 5000-801 Vila Real, Portugal.ORCID 0000-0001-6291-8413
Naouel KlibiLaboratory of Microorganisms and Active Biomolecules, Department of Biology, Faculty of Sciences of Tunis, University of Tunis, Tunis 1008, Tunisia.
Maria de Lurdes Enes DapkeviciusFaculty of Agricultural and Environmental Sciences, University of the Azores, 9700-042 Angra do Heroísmo, Portugal.ORCID 0000-0003-2146-5627
Patrícia ValentãoChemistry Research Centre (CQ-VR), University of Trás-os-Montes and Alto Douro (UTAD), 5000-801 Vila Real, Portugal.ORCID 0000-0002-0740-4396
Virgílio FalcoREQUIMTE/LAQV, Laboratório de Farmacognosia, Departamento de Química, Faculdade de Farmácia, Universidade do Porto, R. Jorge Viterbo Ferreira, n° 228, 4050-313 Porto, Portugal.ORCID 0000-0003-2742-0622
Patrícia PoetaMicrobiology and Antibiotic Resistance Team (MicroART), Department of Veterinary Sciences, University of Trás-os-Montes and Alto Douro (UTAD), 5000-801 Vila Real, Portugal.ORCID 0000-0003-0925-689X

Funding

Fundação para a Ciência e a Tecnologia SFRH/BD/04576/2020Fundação para a Ciência e a Tecnologia SFRH/BD/137947/2018Fundação para a Ciência e a Tecnologia UIDB/50006/2020Fundação para a Ciência e a Tecnologia UIDP/50006/2020
6 · The paper itself

Abstract

The emergence of antibiotic-resistance in bacteria has limited the ability to treat bacterial infections, besides increasing their morbidity and mortality at the global scale. The need for alternative solutions to deal with this problem is urgent and has brought about a renewed interest in natural products as sources of potential antimicrobials. The wine industry is responsible for the production of vast amounts of waste and by-products, with associated environmental problems. These residues are rich in bioactive secondary metabolites, especially phenolic compounds. Some phenolics are bacteriostatic/bactericidal against several pathogenic bacteria and may have a synergistic action towards antibiotics, mitigating or reverting bacterial resistance to these drugs. Complex phenolic mixtures, such as those present in winemaking residues (pomace, skins, stalks, leaves, and especially seeds), are even more effective as antimicrobials and could be used in combined therapy, thereby contributing to management of the antibiotic resistance crisis. This review focuses on the potentialities of winemaking by-products, their extracts, and constituents as chemotherapeutic antibacterial agents.

Indexed as

Anti-Bacterial AgentsAnti-Infective AgentsAntioxidantsDrug Resistance, MicrobialPhenolsAnti-Bacterial AgentsAnti-Infective AgentsAntioxidantsPhenolsantibacterial activityantibiotic resistancegrape by-productsphenolic compounds

Identifiers

PMID33923843
PMCPMC8073494

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.